- Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years
- Bioengineered T cells, called CTL019 cells, function as cancer hunters, killing the leukemia cells that normally evade regular T cell surveillance.
- The personalized cell therapy reprograms a patient’s immune system and offers the potential of long-term success
Benefits Persist in T Cell Therapy For Children With Relapsed Leukemia
12. 7. 14 by Alex Klokus